Jamal Christopher Perry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jamal Christopher Perry has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Ivan Cancarevic
Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
4 shared publications - Omar Aaron Oudit
Department of Internal Medicine, Brookdale University Hospital Medical Center, Brooklyn, NY 11212, USA
4 shared publications - Sadaf Faiz
Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
4 shared publications Tayná M. Schuetz
Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
4 shared publications- Temitayo Adebowale
Department of Biomedical Science, Columbia Irving Medical Center, New York, NY 10032, USA
4 shared publications - Abdulrahman Atasi
Department of Internal Medicine, Brookdale University Hospital Medical Center, Brooklyn, NY 11212, USA
3 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by MDPI AG in Preprints.org
The Clinical Impacts of Aspirin Use on Adverse in Hospital Outcomes in Decompensated Cirrhosis with Ascites: A National Evaluation
Introduction Aspirin initially recognized for its anti-inflammatory, antipyretic and analgesic properties hold a prominent role in the treatment of cardiovascular disease. Cyclooxygenase, COX, 1 and 2 activity in cirrhotic liver disease has been studied by several groups and stratified into COX dependent and independent mechanisms. COX2 gene expression has been identified to be significantly increased in cirrhotic liver disease and various other states of chronic hepatic inflammation. Our study investigates the relationship of aspirin use, an established COX inhibitor, and outcomes in patients hospitalized with ascitic cirrhosis. Methodology The National Inpatient Sample, NIS, database from 2017 to 2022 was analyzed for patients age >18 who were hospitalized for ascitic cirrhosis and its decompensations using ICD-10 diagnostic codes. These patients were further partitioned based on their use of aspirin. The principal outcome of this investigation is in-hospital mortality, with secondary outcomes including odds of portal vein thrombosis, septic shock, ICU admission and acute kidney injury. Secondary outcomes also included the odds of developing hepatic decompensations including need for EGD, hepatorenal syndrome, spontaneous bacterial peritonitis, SBP, developing HCC with and without pulmonary metastasis and of undergoing a transjugular intrahepatic portosystemic shunt, TIPS, procedure. Multivariate logistic regression was applied to the outcomes, and the Charlson Comorbidity Index was used to adjust for confounders. A p-value (pv) of <0.05 was considered statistically significant. Results In our analysis of the NIS, 568,990 patients were identified with ascitic cirrhosis and 11.7% (66,572) of this population were identified to use aspirin. Aspirin use was identified to have a significantly reduced odds of in-patient mortality (adjusted odds ratio) [aOR] 0.540, p value <0.001 95% CI (confidence interval): 0.461 – 0.631. Patients with aspirin use demonstrated significantly reduced odds of portal vein thrombosis, septic shock, ICU admission, and acute kidney injury. Those with ascitic cirrhosis and aspirin use also conveyed reduced odds of developing hepatocellular carcinoma, pulmonary metastasis and hepatic decompensations including hepatorenal syndrome and of undergoing TIPS. Discussion Cirrhotic liver disease remains a global health burden with increasing prevalence and mortality in recent years. This mortality increase remains a critical driver for treatment innovation with continual examination of our repertoire of medications for possible repurposed applications. Elevated COX2 expression has been identified to mediate and accelerate acute and chronic inflammatory states therefore driving the onset of cirrhotic liver disease and hepatic decompensation. Aspirin use and its inhibitory action on COX2 demonstrated a significantly reduced risk of in-hospital mortality. These findings reveal that aspirin use is also linked to a significant reduction in odds of in-hospital mortality, of developing major secondary complications and of developing hepatic decompensation known to increase mortality and morbidity in those with cirrhosis as compared to those who do not use aspirin.
- 15 September 2026
- Published by MDPI AG in Preprints.org
Open AccessThe Clinical Impacts of Aspirin Use on Adverse in Hospital Outcomes in Decompensated Cirrhosis with Ascites: A National Evaluation
Introduction Aspirin initially recognized for its anti-inflammatory, antipyretic and analgesic properties hold a prominent role in the treatment of cardiovascular disease. Cyclooxygenase, COX, 1 and 2 activity in cirrhotic liver disease has been studied by several groups and stratified into COX dependent and independent mechanisms. COX2 gene expression has been identified to be significantly increased in cirrhotic liver disease and various other states of chronic hepatic inflammation. Our study investigates the relationship of aspirin use, an established COX inhibitor, and outcomes in patients hospitalized with ascitic cirrhosis. Methodology The National Inpatient Sample, NIS, database from 2017 to 2022 was analyzed for patients age >18 who were hospitalized for ascitic cirrhosis and its decompensations using ICD-10 diagnostic codes. These patients were further partitioned based on their use of aspirin. The principal outcome of this investigation is in-hospital mortality, with secondary outcomes including odds of portal vein thrombosis, septic shock, ICU admission and acute kidney injury. Secondary outcomes also included the odds of developing hepatic decompensations including need for EGD, hepatorenal syndrome, spontaneous bacterial peritonitis, SBP, developing HCC with and without pulmonary metastasis and of undergoing a transjugular intrahepatic portosystemic shunt, TIPS, procedure. Multivariate logistic regression was applied to the outcomes, and the Charlson Comorbidity Index was used to adjust for confounders. A p-value (pv) of <0.05 was considered statistically significant. Results In our analysis of the NIS, 568,990 patients were identified with ascitic cirrhosis and 11.7% (66,572) of this population were identified to use aspirin. Aspirin use was identified to have a significantly reduced odds of in-patient mortality (adjusted odds ratio) [aOR] 0.540, p value <0.001 95% CI (confidence interval): 0.461 – 0.631. Patients with aspirin use demonstrated significantly reduced odds of portal vein thrombosis, septic shock, ICU admission, and acute kidney injury. Those with ascitic cirrhosis and aspirin use also conveyed reduced odds of developing hepatocellular carcinoma, pulmonary metastasis and hepatic decompensations including hepatorenal syndrome and of undergoing TIPS. Discussion Cirrhotic liver disease remains a global health burden with increasing prevalence and mortality in recent years. This mortality increase remains a critical driver for treatment innovation with continual examination of our repertoire of medications for possible repurposed applications. Elevated COX2 expression has been identified to mediate and accelerate acute and chronic inflammatory states therefore driving the onset of cirrhotic liver disease and hepatic decompensation. Aspirin use and its inhibitory action on COX2 demonstrated a significantly reduced risk of in-hospital mortality. These findings reveal that aspirin use is also linked to a significant reduction in odds of in-hospital mortality, of developing major secondary complications and of developing hepatic decompensation known to increase mortality and morbidity in those with cirrhosis as compared to those who do not use aspirin.
- Open Access
- 18 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15  (10) , 3894
The Impact of Aspirin Use on In-Hospital Outcomes and Metastatic Disease in Colorectal Cancer: An Evaluation of the National Inpatient Sample
Background: Aspirin, initially recognized for its anti-inflammatory, antipyretic and analgesic properties, holds a prominent role in the treatment of cardiovascular disease. The utility of aspirin in cancer therapeutics has been explored and stratified into COX-dependent and -independent mechanisms. COX2 gene expression has been demonstrated to be significantly upregulated in colorectal cancer and various other gastrointestinal malignancies including pancreatic, esophageal, and gastric cancer. This study investigates the relationship of aspirin use and outcomes in patients with colorectal cancer. Methods: The Nationwide Inpatient Sample (NIS) database from 2017 to 2022 was analyzed for patients age > 18 who were hospitalized for colorectal cancer and its decompensations using ICD-10 diagnostic codes. These patients were further stratified based on the long-term use of aspirin. The principal outcome of this investigation are the odds of in-hospital mortality, with secondary outcomes including odds of pulmonary embolism, portal vein thrombosis, acute kidney injury, septic shock, requiring an ICU level of care and odds of hepatic, pulmonary, gastrointestinal and peritoneal or retroperitoneal metastatic disease. Multivariate logistic regression accounting for hospital and patient characteristics was implemented for analysis, with the Charlson Comorbidity Index used to adjust for coexisting comorbidity burden; a p-value (p) of p value < 0.001 95% CI (confidence interval): 0.460–0.617. Patients with aspirin use also demonstrated significantly reduced odds of adverse outcomes and gastrointestinal, hepatic, pulmonary and retroperitoneal/peritoneal metastasis; (aOR 0.606, 95% CI: 0.564–0.653, p < 0.001), (aOR 0.628, 95% CI: 0.582–0.678, p < 0.001), (aOR 0.676, 95% CI: 0.605–0.755, p < 0.001) and (aOR 0.751, 95% CI: 0.685–0.825, p < 0.001) respectively. Conclusions: In recent years, there has been an alarming increase in incidence of colorectal cancer, particularly amongst younger individuals with increased associated mortality. This mortality increase, albeit alarming, is a driving force for treatment innovation with continual examination of our repertoire of medications for possible repurposed applications. COX2-mediated signaling serves as a key promotor of tumorigenic molecular signaling that directly contributes to tumor cell proliferation, angiogenesis and metastasis in colorectal cancer. Aspirin use and its inhibitory action on COX2 demonstrated a significantly reduced odds of in-hospital mortality. Aspirin use is also associated with significantly reduced odds of developing metastatic disease to the liver, gastrointestinal system, lungs and peritoneum in patients with colorectal cancer. These findings convey that aspirin use reduces the likelihood of in-hospital mortality, major comorbid conditions and of developing metastatic disease as compared to those who do not use aspirin.
- 18 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15  (10) , 3894
Open AccessThe Impact of Aspirin Use on In-Hospital Outcomes and Metastatic Disease in Colorectal Cancer: An Evaluation of the National Inpatient Sample
Background: Aspirin, initially recognized for its anti-inflammatory, antipyretic and analgesic properties, holds a prominent role in the treatment of cardiovascular disease. The utility of aspirin in cancer therapeutics has been explored and stratified into COX-dependent and -independent mechanisms. COX2 gene expression has been demonstrated to be significantly upregulated in colorectal cancer and various other gastrointestinal malignancies including pancreatic, esophageal, and gastric cancer. This study investigates the relationship of aspirin use and outcomes in patients with colorectal cancer. Methods: The Nationwide Inpatient Sample (NIS) database from 2017 to 2022 was analyzed for patients age > 18 who were hospitalized for colorectal cancer and its decompensations using ICD-10 diagnostic codes. These patients were further stratified based on the long-term use of aspirin. The principal outcome of this investigation are the odds of in-hospital mortality, with secondary outcomes including odds of pulmonary embolism, portal vein thrombosis, acute kidney injury, septic shock, requiring an ICU level of care and odds of hepatic, pulmonary, gastrointestinal and peritoneal or retroperitoneal metastatic disease. Multivariate logistic regression accounting for hospital and patient characteristics was implemented for analysis, with the Charlson Comorbidity Index used to adjust for coexisting comorbidity burden; a p-value (p) of p value < 0.001 95% CI (confidence interval): 0.460–0.617. Patients with aspirin use also demonstrated significantly reduced odds of adverse outcomes and gastrointestinal, hepatic, pulmonary and retroperitoneal/peritoneal metastasis; (aOR 0.606, 95% CI: 0.564–0.653, p < 0.001), (aOR 0.628, 95% CI: 0.582–0.678, p < 0.001), (aOR 0.676, 95% CI: 0.605–0.755, p < 0.001) and (aOR 0.751, 95% CI: 0.685–0.825, p < 0.001) respectively. Conclusions: In recent years, there has been an alarming increase in incidence of colorectal cancer, particularly amongst younger individuals with increased associated mortality. This mortality increase, albeit alarming, is a driving force for treatment innovation with continual examination of our repertoire of medications for possible repurposed applications. COX2-mediated signaling serves as a key promotor of tumorigenic molecular signaling that directly contributes to tumor cell proliferation, angiogenesis and metastasis in colorectal cancer. Aspirin use and its inhibitory action on COX2 demonstrated a significantly reduced odds of in-hospital mortality. Aspirin use is also associated with significantly reduced odds of developing metastatic disease to the liver, gastrointestinal system, lungs and peritoneum in patients with colorectal cancer. These findings convey that aspirin use reduces the likelihood of in-hospital mortality, major comorbid conditions and of developing metastatic disease as compared to those who do not use aspirin.
- Open Access
- 15 April 2026
- Published by MDPI AG in Preprints.org
The Protective Effects of Aspirin Use from Adverse In Hospital Outcomes and Metastatic Disease in Colorectal Cancer: An Evaluation of the National Inpatient Sample
Introduction Aspirin initially recognized for its anti-inflammatory, antipyretic and analgesic properties hold a prominent role in the treatment of cardiovascular disease. The utility of aspirin in cancer therapeutics has been explored and stratified into COX dependent and independent mechanisms. COX2 gene expression has been demonstrated to be significantly upregulated in colorectal cancer and various other gastrointestinal malignancies including pancreatic, esophageal, and gastric cancer. This study investigates the relationship of aspirin use and outcomes in patients with colorectal cancer. Methodology The Nationwide Inpatient Sample (NIS) database from 2017 to 2022 was analyzed for patients age >18 who were hospitalized for colorectal cancer and its decompensations using ICD-10 diagnostic codes. These patients were further stratified based on the long term use of aspirin. The principal outcome of this investigation is in-hospital mortality, with secondary outcomes including rates of pulmonary embolism, portal vein thrombosis, acute kidney injury and need for renal replacement therapy, septic shock and rates of hepatic, pulmonary, gastrointestinal and peritoneal or retroperitoneal metastatic disease. Multivariate logistic regression accounting for hospital and patient characteristics was implemented for analysis, with the Charlson Comorbidity Index used to adjust for coexisting comorbidity burden; a p-value (p) of Results In our analysis of the NIS, 569,306 patients were identified with colorectal cancer and 11.7% (66,608) of this population were identified with long term use of aspirin. Aspirin use was identified to have a significantly reduced odds of in-patient mortality (adjusted odds ratio) [aOR] 0.530, p value Conclusion In recent years there has been an alarming increase in incidence of colorectal cancer, particularly amongst younger individuals with increased associated mortality. This mortality increase, albeit alarming, is a driving force for treatment innovation with continual examination of our repertoire of medications for possible repurposed applications. COX2 mediated signaling serves as a key promotor of tumorigenic molecular signaling that directly contribute to tumor cell proliferation, angiogenesis and metastasis in colorectal cancer. Aspirin use and its inhibitory action on COX2 demonstrated a significantly reduced risk of in-hospital mortality. Aspirin use is also linked to a significant reduction in odds of developing metastatic disease to the liver, gastrointestinal system, lungs and peritoneum in patients with colorectal cancer. These findings reveal that aspirin exerts shielding effects against in-hospital mortality and protects patients with colorectal cancer from the development of major comorbid conditions and metastatic disease as compared to those who do not use aspirin.
- 15 April 2026
- Published by MDPI AG in Preprints.org
Open AccessThe Protective Effects of Aspirin Use from Adverse In Hospital Outcomes and Metastatic Disease in Colorectal Cancer: An Evaluation of the National Inpatient Sample
Introduction Aspirin initially recognized for its anti-inflammatory, antipyretic and analgesic properties hold a prominent role in the treatment of cardiovascular disease. The utility of aspirin in cancer therapeutics has been explored and stratified into COX dependent and independent mechanisms. COX2 gene expression has been demonstrated to be significantly upregulated in colorectal cancer and various other gastrointestinal malignancies including pancreatic, esophageal, and gastric cancer. This study investigates the relationship of aspirin use and outcomes in patients with colorectal cancer. Methodology The Nationwide Inpatient Sample (NIS) database from 2017 to 2022 was analyzed for patients age >18 who were hospitalized for colorectal cancer and its decompensations using ICD-10 diagnostic codes. These patients were further stratified based on the long term use of aspirin. The principal outcome of this investigation is in-hospital mortality, with secondary outcomes including rates of pulmonary embolism, portal vein thrombosis, acute kidney injury and need for renal replacement therapy, septic shock and rates of hepatic, pulmonary, gastrointestinal and peritoneal or retroperitoneal metastatic disease. Multivariate logistic regression accounting for hospital and patient characteristics was implemented for analysis, with the Charlson Comorbidity Index used to adjust for coexisting comorbidity burden; a p-value (p) of Results In our analysis of the NIS, 569,306 patients were identified with colorectal cancer and 11.7% (66,608) of this population were identified with long term use of aspirin. Aspirin use was identified to have a significantly reduced odds of in-patient mortality (adjusted odds ratio) [aOR] 0.530, p value Conclusion In recent years there has been an alarming increase in incidence of colorectal cancer, particularly amongst younger individuals with increased associated mortality. This mortality increase, albeit alarming, is a driving force for treatment innovation with continual examination of our repertoire of medications for possible repurposed applications. COX2 mediated signaling serves as a key promotor of tumorigenic molecular signaling that directly contribute to tumor cell proliferation, angiogenesis and metastasis in colorectal cancer. Aspirin use and its inhibitory action on COX2 demonstrated a significantly reduced risk of in-hospital mortality. Aspirin use is also linked to a significant reduction in odds of developing metastatic disease to the liver, gastrointestinal system, lungs and peritoneum in patients with colorectal cancer. These findings reveal that aspirin exerts shielding effects against in-hospital mortality and protects patients with colorectal cancer from the development of major comorbid conditions and metastatic disease as compared to those who do not use aspirin.
- Open Access
- 10 April 2026
- Published by MDPI AG in Preprints.org
Shielding Effects of Aspirin Use from Adverse in Hospital Outcomes in Non-Metastatic Pancreatic Cancer: An Evaluation of the National Inpatient Sample
Aspirin initially recognized for its anti-inflammatory, antipyretic and analgesic properties hold a prominent role in the treatment of cardiovascular disease. The utility of aspirin in cancer therapeutics has been studied by several groups and stratified into COX dependent and independent mechanisms. COX2 gene expression was significantly increased in colorectal cancer and various other gastrointestinal malignancies; pancreatic, esophageal and gastric cancer. Our study investigates the relationship of aspirin use and outcomes in patients with non metastatic pancreatic cancer. Methodology The Nationwide Inpatient Sample, NIS, database from 2017 to 2022 was analyzed for patients age >18 who were hospitalized for non metastatic pancreatic cancer and its decompensations using ICD-10 diagnostic codes. These patients were partitioned based on their use of aspirin. The principal outcome of this investigation is in-hospital mortality, with secondary outcomes including rates of. Multivariate logistic regression was applied to the outcomes, and the Charlson Comorbidity Index was used to adjust for confounders. A p-value (pv) of <0.05 was considered statistically significant. Results In our analysis of the NIS, 139,579 patients were identified with non-metastatic pancreatic cancer and 19,475 patients (13.9%) were identified with aspirin use and 120,177 patients (86.1%) with no aspirin use. Aspirin use was identified to have a significantly reduced odds of in-patient mortality (adjusted odds ratio) (aOR) 0.531; p value <0.001 95% CI (confidence interval): 0.419 – 0.673. Patients with aspirin use also demonstrated significantly reduced odds of developing a pulmonary embolism, portal vein thrombosis, acute kidney injury, renal replacment therapy, septic shock, of requiring an ICU level of care. Conclusion The mortality increase in pancreatic cancer mortality, albeit alarming, serves as a driving force for treatment innovation with continual examination of current treatments and our repertoire of medications for possible repurposed applications. COX2 mediated signaling serves as a key promotor of tumorigenic molecular signaling that directly contribute to tumor cell proliferation, angiogenesis and metastasis in pancreatic cancer. Aspirin use and its inhibitory action on COX2 demonstrated a significantly reduced risk of in-hospital mortality. Aspirin use is also linked to a significant reduction in odds of developing non metastatic pancreatic cancer. Our findings support that aspirin exerts shielding effects against in-hospital mortality and protects patients with non metastatic pancreatic cancer from the development of major in hospital comorbidities as compared to those who do not use aspirin.
- 10 April 2026
- Published by MDPI AG in Preprints.org
Open AccessShielding Effects of Aspirin Use from Adverse in Hospital Outcomes in Non-Metastatic Pancreatic Cancer: An Evaluation of the National Inpatient Sample
Aspirin initially recognized for its anti-inflammatory, antipyretic and analgesic properties hold a prominent role in the treatment of cardiovascular disease. The utility of aspirin in cancer therapeutics has been studied by several groups and stratified into COX dependent and independent mechanisms. COX2 gene expression was significantly increased in colorectal cancer and various other gastrointestinal malignancies; pancreatic, esophageal and gastric cancer. Our study investigates the relationship of aspirin use and outcomes in patients with non metastatic pancreatic cancer. Methodology The Nationwide Inpatient Sample, NIS, database from 2017 to 2022 was analyzed for patients age >18 who were hospitalized for non metastatic pancreatic cancer and its decompensations using ICD-10 diagnostic codes. These patients were partitioned based on their use of aspirin. The principal outcome of this investigation is in-hospital mortality, with secondary outcomes including rates of. Multivariate logistic regression was applied to the outcomes, and the Charlson Comorbidity Index was used to adjust for confounders. A p-value (pv) of <0.05 was considered statistically significant. Results In our analysis of the NIS, 139,579 patients were identified with non-metastatic pancreatic cancer and 19,475 patients (13.9%) were identified with aspirin use and 120,177 patients (86.1%) with no aspirin use. Aspirin use was identified to have a significantly reduced odds of in-patient mortality (adjusted odds ratio) (aOR) 0.531; p value <0.001 95% CI (confidence interval): 0.419 – 0.673. Patients with aspirin use also demonstrated significantly reduced odds of developing a pulmonary embolism, portal vein thrombosis, acute kidney injury, renal replacment therapy, septic shock, of requiring an ICU level of care. Conclusion The mortality increase in pancreatic cancer mortality, albeit alarming, serves as a driving force for treatment innovation with continual examination of current treatments and our repertoire of medications for possible repurposed applications. COX2 mediated signaling serves as a key promotor of tumorigenic molecular signaling that directly contribute to tumor cell proliferation, angiogenesis and metastasis in pancreatic cancer. Aspirin use and its inhibitory action on COX2 demonstrated a significantly reduced risk of in-hospital mortality. Aspirin use is also linked to a significant reduction in odds of developing non metastatic pancreatic cancer. Our findings support that aspirin exerts shielding effects against in-hospital mortality and protects patients with non metastatic pancreatic cancer from the development of major in hospital comorbidities as compared to those who do not use aspirin.
- 24 September 2024
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 77, 83-88
Racial and ethnic disparities in clinical outcomes among patients with takotsubo syndrome; A nation-wide analysis
- 24 September 2024
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 77, 83-88
Racial and ethnic disparities in clinical outcomes among patients with takotsubo syndrome; A nation-wide analysis
- Open Access
- 26 May 2023
- Published by Springer Nature in Cureus
- Vol. 15  (5) , e39522
Alcohol Abuse as a Silent Risk Factor for Purpura Fulminans and the Importance of Pneumococcal Vaccination
Purpura fulminans (PF) is a rare presentation of disseminated intravascular coagulopathy (DIC) and a life-threatening complication of septic shock. DIC can present with bleeding and thrombosis in acute settings, making its management exceptionally challenging. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. We report a case of a 47-year-old patient with a history of alcohol abuse and marijuana use with a bizarre presentation of copious diarrhea and altered mental status. The patient was subsequently admitted to the intensive care unit (ICU) for acute respiratory failure and septic shock secondary to Streptococcus pneumoniae bacteremia complicated by DIC. Unfortunately, the patient's condition worsened with multiorgan failure and purpura fulminans, leading to extensive necrosis of all his extremities, with the involvement of his lips, nose, and genitals. Unfortunately, despite aggressive interventions, he continued to deteriorate and ultimately was transitioned to comfort care before he expired. In the literature, there is only one reported case of PF in an individual with alcohol abuse. However, the frequency and severity of pneumococcal infections in individuals with a history of alcohol abuse are much higher than in the general population. PF is a devastating complication of Streptococcus pneumoniae, with a mortality of 43%. We hope that this case will continue highlighting the importance of vaccinating patients with a history of alcohol abuse with the pneumococcal vaccine.
- 26 May 2023
- Published by Springer Nature in Cureus
- Vol. 15  (5) , e39522
Open AccessAlcohol Abuse as a Silent Risk Factor for Purpura Fulminans and the Importance of Pneumococcal Vaccination
Purpura fulminans (PF) is a rare presentation of disseminated intravascular coagulopathy (DIC) and a life-threatening complication of septic shock. DIC can present with bleeding and thrombosis in acute settings, making its management exceptionally challenging. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. We report a case of a 47-year-old patient with a history of alcohol abuse and marijuana use with a bizarre presentation of copious diarrhea and altered mental status. The patient was subsequently admitted to the intensive care unit (ICU) for acute respiratory failure and septic shock secondary to Streptococcus pneumoniae bacteremia complicated by DIC. Unfortunately, the patient's condition worsened with multiorgan failure and purpura fulminans, leading to extensive necrosis of all his extremities, with the involvement of his lips, nose, and genitals. Unfortunately, despite aggressive interventions, he continued to deteriorate and ultimately was transitioned to comfort care before he expired. In the literature, there is only one reported case of PF in an individual with alcohol abuse. However, the frequency and severity of pneumococcal infections in individuals with a history of alcohol abuse are much higher than in the general population. PF is a devastating complication of Streptococcus pneumoniae, with a mortality of 43%. We hope that this case will continue highlighting the importance of vaccinating patients with a history of alcohol abuse with the pneumococcal vaccine.
- Open Access
- 30 December 2022
- Published by Springer Nature in Cureus
- Vol. 14  (12) , e33123
Cardiac Tamponade in Patients With Breast Cancer: A Systematic Review
Cardiac tamponade is a rare presentation in breast cancer and may be associated with poor prognosis. In this article, we reviewed the characteristics and survival outcomes of patients with breast cancer who developed cardiac tamponade. Three databases (PubMed, EMBASE and SCOPUS) were searched for relevant articles published from 1978 to 2022 and 16 articles were identified comprising 64 cases. The median age of the cases was 52 years. Cardiac tamponade was diagnosed with echocardiogram or computerized tomography of the chest or both in 91.9%, 1.6% and 6.5% of the cases, respectively. Cytology of the pericardial fluid was done in 90.5% of the cases while biopsy in addition to cytology was done in 9.5% of cases. Tamponade was proven to be malignant in 97.4% of the cases. The initial treatment for tamponade was pericardiocentesis. Adjunct therapies ranged from the insertion of a pericardial window, pericardiectomy, radiotherapy and chemotherapy. The median time from the first treatment of breast cancer to the onset of tamponade was 24 months while the median survival following diagnosis of tamponade was 13 months. There was no significant correlation (spearman rank-sum correlation coefficient = 0.35, p = 0.165) between time to tamponade (interval time from the first diagnosis of breast cancer and the onset of cardiac tamponade) and survival. Cardiac tamponade may adversely affect survival in patients with breast cancer. Early diagnosis with echocardiogram and cytology may guide management and expectations. Further observational studies are needed to determine the predictors of cardiac tamponade and optimal treatment in patients with breast cancer.
- 30 December 2022
- Published by Springer Nature in Cureus
- Vol. 14  (12) , e33123
Open AccessCardiac Tamponade in Patients With Breast Cancer: A Systematic Review
Cardiac tamponade is a rare presentation in breast cancer and may be associated with poor prognosis. In this article, we reviewed the characteristics and survival outcomes of patients with breast cancer who developed cardiac tamponade. Three databases (PubMed, EMBASE and SCOPUS) were searched for relevant articles published from 1978 to 2022 and 16 articles were identified comprising 64 cases. The median age of the cases was 52 years. Cardiac tamponade was diagnosed with echocardiogram or computerized tomography of the chest or both in 91.9%, 1.6% and 6.5% of the cases, respectively. Cytology of the pericardial fluid was done in 90.5% of the cases while biopsy in addition to cytology was done in 9.5% of cases. Tamponade was proven to be malignant in 97.4% of the cases. The initial treatment for tamponade was pericardiocentesis. Adjunct therapies ranged from the insertion of a pericardial window, pericardiectomy, radiotherapy and chemotherapy. The median time from the first treatment of breast cancer to the onset of tamponade was 24 months while the median survival following diagnosis of tamponade was 13 months. There was no significant correlation (spearman rank-sum correlation coefficient = 0.35, p = 0.165) between time to tamponade (interval time from the first diagnosis of breast cancer and the onset of cardiac tamponade) and survival. Cardiac tamponade may adversely affect survival in patients with breast cancer. Early diagnosis with echocardiogram and cytology may guide management and expectations. Further observational studies are needed to determine the predictors of cardiac tamponade and optimal treatment in patients with breast cancer.
- Open Access
- 4 December 2022
- Published by Springer Nature in Cureus
- Vol. 14  (12) , e32217
BRASH Syndrome Presenting With Idioventricular Escape Rhythm in a Patient With Trifascicular Block
Bradycardia, renal failure, atrioventricular (AV) nodal disease, shock, and hyperkalemia (BRASH) syndrome is a well-recognized constellation of distinct clinicopathologic entities comprising bradycardia, renal failure, AV nodal disease, shock, and hyperkalemia. Our patient is an 89-year-old female with a past medical history significant for hypertension and diabetes, who was newly started on labetalol and had recent gastroenteritis; she presented to our Emergency Department with bradycardia and shock. Upon presentation, she showed physical signs of volume depletion, and her blood pressure was 50 mmHg systolic and heart rate was 25 beats per minute. The initial electrocardiogram showed an idioventricular rhythm. The laboratory workup revealed hyperkalemia. The patient was given repeated doses of atropine with no significant response. She was resuscitated with isotonic fluids. The patient improved clinically, her blood pressure stabilized, her potassium level, renal function, and heart rate were normalized, and normal sinus rhythm was restored with a narrow QRS complex. A diagnosis of BRASH syndrome was made retrospectively. Overall, the treatment of this syndrome is largely symptomatic. Hemodynamic support with fluid and treatment of hyperkalemia remains the goal of care. The overall prognosis is good if identified early and managed appropriately.
- 4 December 2022
- Published by Springer Nature in Cureus
- Vol. 14  (12) , e32217
Open AccessBRASH Syndrome Presenting With Idioventricular Escape Rhythm in a Patient With Trifascicular Block
Bradycardia, renal failure, atrioventricular (AV) nodal disease, shock, and hyperkalemia (BRASH) syndrome is a well-recognized constellation of distinct clinicopathologic entities comprising bradycardia, renal failure, AV nodal disease, shock, and hyperkalemia. Our patient is an 89-year-old female with a past medical history significant for hypertension and diabetes, who was newly started on labetalol and had recent gastroenteritis; she presented to our Emergency Department with bradycardia and shock. Upon presentation, she showed physical signs of volume depletion, and her blood pressure was 50 mmHg systolic and heart rate was 25 beats per minute. The initial electrocardiogram showed an idioventricular rhythm. The laboratory workup revealed hyperkalemia. The patient was given repeated doses of atropine with no significant response. She was resuscitated with isotonic fluids. The patient improved clinically, her blood pressure stabilized, her potassium level, renal function, and heart rate were normalized, and normal sinus rhythm was restored with a narrow QRS complex. A diagnosis of BRASH syndrome was made retrospectively. Overall, the treatment of this syndrome is largely symptomatic. Hemodynamic support with fluid and treatment of hyperkalemia remains the goal of care. The overall prognosis is good if identified early and managed appropriately.
- Open Access
- 22 October 2020
- Published by Springer Nature in Cureus
- Vol. 12  (10)
Diabetic Cardiomyopathy as a Clinical Entity: Is It a Myth?
Dilated cardiomyopathy (DCM) is a common form of cardiomyopathy that affects the cardiac muscle. It is a life-threatening condition that causes heart failure as it decreases the myocardial ability to pump sufficient blood throughout the body. Numerous causes trigger DCM without pathophysiology; however, the key concept is a decrease in the systolic function of either the left ventricle or of both the left and right ventricles. Long-term diabetes plays an important role in the pathogenesis of DCM in the form of diabetic cardiomyopathy. Diabetic cardiomyopathy is a non-ischemic form of DCM, which is associated with diabetes. It is unrelated to atherosclerosis and hypertension. The PubMed and Google Scholar databases were used to identify the relevant studies related to diabetes and DCM. We found that diabetes was associated with cardiac muscle injury by activating the renin-angiotensin-aldosterone system, myocardial inflammation, and fibrosis. Based on the available data, we concluded that there is strong evidence to support the interrelation of DCM and diabetes.
- 22 October 2020
- Published by Springer Nature in Cureus
- Vol. 12  (10)
Open AccessDiabetic Cardiomyopathy as a Clinical Entity: Is It a Myth?
Dilated cardiomyopathy (DCM) is a common form of cardiomyopathy that affects the cardiac muscle. It is a life-threatening condition that causes heart failure as it decreases the myocardial ability to pump sufficient blood throughout the body. Numerous causes trigger DCM without pathophysiology; however, the key concept is a decrease in the systolic function of either the left ventricle or of both the left and right ventricles. Long-term diabetes plays an important role in the pathogenesis of DCM in the form of diabetic cardiomyopathy. Diabetic cardiomyopathy is a non-ischemic form of DCM, which is associated with diabetes. It is unrelated to atherosclerosis and hypertension. The PubMed and Google Scholar databases were used to identify the relevant studies related to diabetes and DCM. We found that diabetes was associated with cardiac muscle injury by activating the renin-angiotensin-aldosterone system, myocardial inflammation, and fibrosis. Based on the available data, we concluded that there is strong evidence to support the interrelation of DCM and diabetes.
- Open Access
- 14 October 2020
- Published by Springer Nature in Cureus
- Vol. 12  (10)
Unraveling the Mysteries of Restless Leg Syndrome
Restless leg syndrome (RLS) or Willis-Ekbom disease (WED) is an under-diagnosed, chronic, and progressive primary sensory-motor disorder. It is characterized by an uncontrollable urge to move the legs due to uncomfortable and sometimes painful sensations, with a diurnal variation. RLS can lead to severe sleep disturbances, a usual cause of consultation. The pathophysiology is known partially, and it is believed that there is an association between the different variants of genetic mutations combined with dopaminergic and brain iron dysregulation, which plays an important role. The data used for this study were extracted from the articles found in the PubMed database that discuss different gene variants, pathophysiology, and various methods of treatment. They also highlight the role of iron in the pathogenesis of RLS as it is required for the synthesis of tyrosine hydroxylase, which is the rate-limiting step for dopamine synthesis. This review article provides a clinically useful overview of RLS in terms of pathophysiological findings, its genetic associations, and therapeutic options by using the currently available literature. Because RLS presents with vague symptoms and shares similarities with many other diseases, it might be overlooked by many physicians resulting in underdiagnosis and under-treatment. While these discoveries provide a breakthrough in understanding the details of RLS, further studies are recommended as these studies are limited to animal models and provide a limited representation of the general population.
- 14 October 2020
- Published by Springer Nature in Cureus
- Vol. 12  (10)
Open AccessUnraveling the Mysteries of Restless Leg Syndrome
Restless leg syndrome (RLS) or Willis-Ekbom disease (WED) is an under-diagnosed, chronic, and progressive primary sensory-motor disorder. It is characterized by an uncontrollable urge to move the legs due to uncomfortable and sometimes painful sensations, with a diurnal variation. RLS can lead to severe sleep disturbances, a usual cause of consultation. The pathophysiology is known partially, and it is believed that there is an association between the different variants of genetic mutations combined with dopaminergic and brain iron dysregulation, which plays an important role. The data used for this study were extracted from the articles found in the PubMed database that discuss different gene variants, pathophysiology, and various methods of treatment. They also highlight the role of iron in the pathogenesis of RLS as it is required for the synthesis of tyrosine hydroxylase, which is the rate-limiting step for dopamine synthesis. This review article provides a clinically useful overview of RLS in terms of pathophysiological findings, its genetic associations, and therapeutic options by using the currently available literature. Because RLS presents with vague symptoms and shares similarities with many other diseases, it might be overlooked by many physicians resulting in underdiagnosis and under-treatment. While these discoveries provide a breakthrough in understanding the details of RLS, further studies are recommended as these studies are limited to animal models and provide a limited representation of the general population.